| HEALTH POLICY |
| PHP1 |
| INTEGRATING HEALTH ECONOMICS INTO THE PRODUCT DECISION- MAKING PROCESS: LESSONS LEARNED FROM DECISION-MAKERS
Gevirtz FO1, Lutz JB2, Gao X1, Brooks EA1, 1PPD Development, Morrisville, NC, USA; 23M Health Care, St. Paul, MN, USA |
| PHP2 |
| GASTROINTESTINAL DRUG POLICY, DRUG SELECTION AND RESOURCE UTILIZATION - A COMPARISON OF THE CANADIAN PROVINCES OF QUEBEC AND ONTARIO
Bell NR1, Sheehy O2, LeLorier J2, de Boer D3, Grace E4, Jacobs P1, 1University of Alberta, Edmonton, AB, Canada; 2University of Montreal, Montreal, QC, Canada; 3ICES, Toronto, ON, Canada; 4Astra Zeneca (Canada), Mississauga, ON, Canada |
| PHP3 |
| MACRO-ECONOMIC ANALYSIS OF HEROIN MARKETS IN THE EU AND THE IMPACT OF SUBSTITUTION TREATMENT
Annemans LJ1, Vanoverbeke N2, Tecco J3, Hariga F4, Carpentier C5, 1Ghent University, HEDM, MEISE, Belgium; 2HEDM, MEISE, Belgium; 3University of Brussels, Brussels, Belgium; 4Modus Vivendi, Brussels, Belgium; 5European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal |
| PHP4 |
| WHAT IS A VALID PRESCRIBING INDICATOR?
Gill D1, Timoney A2, Pagliari C3, Donnan P3, Davey P4, 1Tayside Primary Care Trust, Dundee, UK; 2Tayside Health Board, Dundee, UK; 3University of Dundee, Dundee, UK; 4MEMO, University of Dundee, Dundee, Scotland, UK |
| PHP5 |
| USING PRESCRIBING DATA TO ESTIMATE PREVALENCE OF CHRONIC ILLNESS IN THE REPUBLIC OF IRELAND
McElroy B, University College Cork, Cork, Ireland |
| PHP6 |
| INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT
Mègnigbêto A, Le Lay K, Launois R, REES France, PARIS, France |
| PHP7 |
| PILOT STUDY TO DETERMINE THE DEMOGRAPHICS, REASONS, AND TYPES OF MEDICATIONS PURCHASED IN MEXICO BY US RESIDENTS
Calvillo JP, Lal LS, Texas Southern University - College of Pharmacy, Houston, TX, USA |
| PHP8 |
| THE USE OF ECONOMIC INFORMATION IN HOSPITAL FORMULARY DEVELOPMENT IN A FRENCH REGION
Späth HM, Charavel M, Morelle M, Carrère MO, GRESAC - UMR 5823 du CNRS, Lyon, France |
| PHP9 |
| THE INFLUENCE OF UPDATING THE ISRAELI NATIONAL DRUG LIST ON AVERAGE NUMBER OF DRUGS PRESCRIBED TO A PATIENT
Klang S1, Hammerman A2, Bar-Yosef N2, Lieberman N2, Peterburg Y2, 1Clalit Health Services, Tel Aviv, Israel; 2Clalit Health Services, Tel-Aviv, Israel |
| PHP10 |
| THE ROAD TO JAPAN/KOREA 2002: PROSPECTS FOR JAPANESE PHARMACOECONOMICS
Pang F, Kyoto University, Kyoto, Japan |
| PHP11 |
| REVIEW AND ANALYSIS OF DIFFERENT METHODOLOGIES FOR THE CALCULATION AND DISTRIBUTION OF PRIMARY HEALTH CARE PHARMACEUTICAL BUDGETS IN EUROPE
Gilabert A1, San Miguel L2, Prat A1, Casals A1, 1Servei Catala de la Salut, Barcelona, Spain; 2Cambridge Pharma Consultancy, Cambridge, UK |
| PHP12 |
| BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY DECISION-MAKING
Späth HM, Charavel M, Morelle M, Carrère MO, GRESAC - UMR 5823 du CNRS, Lyon, France |
| PHP13 |
| PHARMACOECONOMICS OF BLOOD TRANSFUSION SAFETY MEASURES: A REVIEW OF THE LITERATURE
Postma M1, Staginnus U2, Ruitenberg E3, 1Groningen University Institute for Drug Exploration / University of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, The Netherlands; 2Baxter, S.L, Madrid, Spain; 3Sanquin Foundation for Blood Supply, Amsterdam, The Netherlands |
| PHP14 |
| THE CURRENT STATUS AND FUTURE PROSPECTS FOR PHARMACOECONOMICS IN GREECE
Karokis A, Christodoulopoulou A, Pangali M, Papageorgiou M, AstraZeneca SA, Athens, Greece |
| PHP15 |
| IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS
Kleinstiver P1, Baladi JF2, 1Katalyst Health Technology Assessments, London, ON, Canada; 2Novartis Canada, Dorval, QC, Canada |
| PHP16 |
| HOW RESPONSIVE ARE OUR HEALTH CENTRES?
Ferreira PL, Coimbra University, Portugal, Coimbra, Portugal |
| PHP17 |
| A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC
de Charro FT1, Rabin RE2, Weijnen T1, 1Erasmus University Rotterdam, Rotterdam, Netherlands; 2EuroQol Group, Rotterdam, Netherlands |
| PHP18 |
| THE CLINICAL PHARMACIST AS A MEMBER OF THE MEDICAL WARD TEAM - A PILOT STUDY
Shilo L, Kleiman-Wexler R, Berebi R, Klang S, Lieberman N, Peterburg Y, Clalit Health Services, Tel Aviv, Israel |
| PHP19 |
| COST OF BLOOD PRODUCTS IN GERMAN HOSPITALS
Spannheimer A1, Mast O2, Schlereth T1, Thate-Waschke I2, Dietrich W3, 1Kendle International Inc, Munich, Germany; 2Bayer Vital GmbH, Leverkusen, Germany; 3Deutsches Herzzentrum, Munich, Germany |
| PHP20 |
| THE ECONOMIC BURDEN OF PHYSICAL INACTIVITY IN SWITZERLAND
Smala AM1, Beeler I2, Martin B3, Brügger O4, Casparis C5, Berger K1, Szucs T2, 1MERG - Medical Economics Research Group, Munich, Germany; 2University Hospital Zurich and Institute for Social and Preventive Medicine, Zurich, Switzerland; 3Bundesamt für Sport, Magglingen, Switzerland; 4Swiss Council for Accident Prevention cap, Berne, Switzerland; 5Schweizerische Unfallversicherungsanstalt (SUVA), Luzern, Switzerland |
| PHP21 |
| COST-BENEFIT ANALYSIS OF PREVENTING PRESCRIBING ERRORS BY HOSPITAL PHARMACISTS
Van den Bemt P, Postma M, Van Roon E, Chow M, Fijn R, Brouwers J, Groningen University Institute for Drug Exploration / University of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen, Netherlands |
| PHP22 |
| PERCEIVED QUALITY OF LIFE AND MEDICINE CONSUMPTION IN ELDERLY OUTPATIENTS
Goicoechea A1, Muñoz M1, Mauleón J2, 1The Basque Country University, Vitoria-Gasteiz, Spain; 2Araba Country Council, Vitoria-Gasteiz, Spain |
| PHP23 |
| HOSPITAL READMISSIONS OF OLDER PEOPLE
Abdelhafiz AH1, Adiotomre JA2, 1Sheffield University, Sheffield, UK; 2Grimsby Hospital, Grimsby, UK |
| PHP24 |
| CRITERIA FOR ASSESSING INTENSIVE CARE UNIT ADMISSIONS FROM THE EMERGENCY ROOM
Gwadry-Sridhar FH1, Martin C2, Chen L2, Priestap F2, Sean K2, 1McMaster University and University of Western Ontario, London, ON, Canada; 2University of Western Ontario, London, ON, Canada |
| PHP25 |
| THE USE OF ATC/DDD METHODOLOGY FOR REVIEWING COST OF DRUG EXPOSURE AT NATIONAL LEVEL
Borissov BN, Popova MJ, Koulaksazova RA, Bulgarian Drug Agency, Sofia, Bulgaria |
| PHP26 |
| THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE
Dickson AJ, Consultant Health Economist, Northallerton, United Kingdom |
| PHP27 |
| THE RELATIONSHIP BETWEEN NATIONAL HEALTH INSURANCE EXPENDITURE AND THE BURDEN OF DISEASE- AN EVDIENCE-BASED STUDY IN TAIWAN
Liang LY, National Yang-Ming University, Taipei, Taiwan |
 |
| ARTHRITIS & OSTEOPOROSIS |
| PAO1 |
| THERAPEUTIC COMPARABILITY OF COX-2 INHIBITORS
Richter A, Sherrill E, von Scheele B, Devlin P, Research Triangle Institute-Health Solutions (RTI-HS), Research Triangle Park, NC, USA |
| PAO2 |
| ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS
Lovas K1, Szende A2, Hodinka L3, Bàlint G3, Héjj G3, 1Semmelweis University, Budapest, Hungary; 2AstraZeneca, Torokbalint, Hungary; 3National Institute of Rheumatology and Physiotherapy, Budapest, Hungary |
| PAO3 |
| COST OF CARE FOR MEMBERS WITH ARTHRITIS - A MANAGED CARE PERSPECTIVE
chaffer M1, Howe A2, Mansukani S1, 1Health Partners, Inc, Philadelphia, PA; 2Grady Health System, Atlanta, GA |
| PAO4 |
| THE COST-EFFECTIVENESS OF CELECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS IN POLAND
Orlewska E, Medical University of Warsaw, Warsaw, Poland |
| PAO5 |
| COST ANALYSIS OF CELECOXIB AND CONVENTIONAL NSAIDS WITH OR WITHOUT GASTROPROTECTIVE AGENTS FOR TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
You JH, Lee KK, Chan FK, Ho SS, Chan TY, Au PS, Lau WH, The Chinese University of Hong Kong, Hong Kong, China |
| PAO6 |
| COST-EFFECTIVENESS ANALYSIS OF USING CELECOXIB IN THE TREATMENT OF OSTEOARTHRITIS
Soto J1, Rejas J2, 1Pharmacia S.A, Madrid, Spain; 2Pfizer S.A, Alcobendas (Madrid), Spain |
| PAO7 |
| AN ECONOMIC EVALUATION OF THE COST OF EDEMA AND SYSTOLIC BLOOD PRESSURE DESTABILIZATION IN COX-2-TREATED PATIENTS WITH OSTEOARTHRITIS AND HYPERTENSION
Becker R1, Burke T2, Williamson T2, Trotter J3, 1Ovation Research Group, Highland Park, IL, USA; 2Pharmacia Corporation, Peapack, NJ, USA; 3Ovation Research Group, Highland Park, IL, USA |
| PAO8 |
| THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS
Barbieri M1, Wong JB2, Drummond MF3, 1University of York, York, UK; 2Tupper Research Institute, New England Medical Center, Boston, MA, USA; 3University of York, York, UK |
| PAO9 |
| DISABILITY, RESOURCE UTILISATION, AND WORK ABSENCES ASSOCIATED WITH OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA): AN INTERNATIONAL DATABASE ANALYSIS
Crawford B1, Evans C1, Turner A2, Karavali M2, 1Mapi Values, Boston, MA, USA; 2Adelphi Ltd, Bollington, UK |
| PAO10 |
| PSYCHOMETRIC VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)
Trudeau E1, Pouchot J2, Hellot S3, Goguel J4, 1Mapi Values, Lyon, France; 2Hôpital Louis Mourier, Paris, France; 3Mapi, Lyon, France, 4Pfizer, Paris, France |
| PAO11 |
| ECONOMIC ANALYSIS OF THE GUIDELINES FOR THE MANAGEMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS IN RESPIRATORY PATIENTS
Moore MR1, Boyter AC1, Walker A2, 1University of Strathclyde, Glasgow, UK; 2University of Glasgow, Glasgow, UK |
| PAO12 |
| DIRECT MEDICAL COST OF OSTEOPOROSIS IN THE UNITED STATES: PROJECTIONS FOR 2000-2025
King AB1, Burge RT2, Worley DJ3, 1Procter & Gamble Pharmaceuticals, Norwich, NY, USA; 2Procter & Gamble Pharmaceuticals, Mason, OH, USA; 3Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA |
| PAO13 |
| UNITED STATES COMMUNITY PHARMACISTS' INTERVENTIONS WITH FEMALE PATIENTS REGARDING OSTEOPOROSIS
Berardo DH, Kanjanarat P, University of Florida, Gainesville, FL, USA |
| PAO14 |
| THE COST-EFFECTIVENESS OF CALCIUM AND VITAMIN D3 SUPPLEMENTATION FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN
Willis M, IHE, The Swedish Institute for Health Economics, Lund, Sweden |
|
|
| CARDIOVASCULAR DISEASE |
| PCV1 |
| LONG-TERM COST-BENEFIT SIMULATION OF SIBUTRAMINE USING A MARKOV MODEL
Evers T, Lauterbach K, University of Cologne, Cologne, Germany |
| PCV2 |
| COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION
Vorobiov P1, Barkagan Z2, Avxentieva M3, Gerasimov V3, Sura M1, Derkach E1, 1RSPOR, Moscow, Russia; 2Altai Medical University, Barnaul, Russia; 3Moscow Medical Academy, Moscow, Russia |
| PCV3 |
| ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE : 1. IN THROMBOEMBOLIC PROPHYLAXIS
Cal ML1, Fabre N2, Cal JC2, 1Université Victor Segalen Bordeaux 2, Bordeaux cedex, France; 2J2C Santé, Mérignac, France |
| PCV4 |
| ASSESSING THE IMPACT OF HYPERLIPIDEMIA TREATMENT WITH PRAVASTATIN AND SIMVASTATIN IN A LARGE COUNTY INSTITUTION
Walker CL1, Milton-Brown J2, Henry A2, Lal LS1, 1Texas Southern University, Houston, TX, USA; 2Drug Information Center of Harris County Hospital District (HCHD), Houston, TX, USA |
| PCV5 |
| IMPACT OF NON-COMPLIANCE ON THE COST-EFFECTIVENESS OF STATIN THERAPY
Hughes DA, Bagust A, University of Liverpool, Liverpool, UK |
| PCV6 |
| AVAPROMISE: A RANDOMIZED CLINICAL TRIAL FOR INCREASING COMPLIANCE THROUGH BEHAVIORAL MODIFICATION IN ESSENTIAL HYPERTENSION
Hamet P1, Campbell N2, Curnew G3, Eastwood C4, Pradhan A5, 1Centre Hospitalier de l'Universite de Montreal, University of Montreal,
Montreal, QC, Canada; 2Health Sciences Centre, University of Calgary, Calgary, AB, Canada; 3Hamilton General Hospital, Hamilton, ON, Canada; 4BTB Associates, Ancaster, ON, Canada; 5Bristol-Myers Squibb Canada, St. Laurent, QC, Canada |
| PCV7 |
| ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE IN ACUTE CORONARY SYNDROMES
Cal ML1, Fabre N2, Cal JC2, 1Université Victor Segalen Bordeaux 2, Bordeaux cedex, France; 2J2C Santé, Mérignac, France |
| PCV8 |
| COST-EFFECTIVENESS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION: DECISION ANALYSIS TAKING INTO ACCOUNT SIDE-EFFECTS
Vorobiov P1, Barkagan Z2, Avxentieva M1, Gerasimov V1, Sura M1, Derkach E1, 1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia; 2Altai Medical University, Barnaul, Russia |
| PCV9 |
| COST-EFFECTIVENESS OF EPTIFIBATIDE IN THE UK BASED ON PURSUIT TRIAL
Brown RE1, Hutton J2, Henderson R3, 1MEDTAP, London, UK; 2MEDTAP International, Inc, London, UK; 3City Hospital, Nottingham, UK |
| PCV10 |
| A PHARMACOECONOMIC ANALYSIS OF PATIENT OUTCOMES IN THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES) IN NORWAY AND CANADA
Doyle J1, Thaulow E2, Casciano R1, Casciano J1, Kopp Z3, 1The Analytica Group, New York, NY, USA; 2University Hospital Oslo, Baerum Postterminal, Sandvika, Norway; 3Pfizer, New York, NY, USA |
| PCV11 |
| THE COST-EFFECTIVENESS OF LEVOSIMENDAN IN SEVERE LOW-OUTPUT HEART FAILURE COMPARED TO DOBUTAMINE BASED ON AN INTERNATIONAL CLINICAL TRIAL (LIDO)
Cleland J1, Takala A2, Apajasalo M2, Zethraeus N3, Kobelt G4, 1University of Hull, Kingston Upon Hull, UK; 2Orion Research Center, Espoo, Finland; 3Stockholm School of Economics, Stockholm, Sweden; 4Health Dynamics International, London, UK |
| PCV12 |
| A COMPARISON OF HEALTH-CARE UTILIZATION AND COSTS OF PATIENTS WITH BRADYCARDIA ONLY AND BRADYCARDIA WITH ATRIAL TACHYARRHYTHMIAS IN THE US, UK AND GERMANY
Sorensen SV1, Halpern MT2, Nuijten M3, De Cock E4, 1MEDTAP International, Bethesda, MD, USA; 2Charles River Associates, Washington, DC, USA; 3MEDTAP International, Jisp, Netherlands; 4MEDTAP International, London, UK |
| PCV13 |
| EFFECT OF AMLODIPINE TREATMENT ON CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATIONS AND COSTS IN PATIENTS WITH CORONARY ARTERY DISEASE IN SPAIN
Galduf J1, Rejas J2, Arocho R3, Arístegui R2, 1Pfizer and Pompeu Fabra University, Barcelona, Spain; 2Pfizer, Madrid, Spain; 3Pfizer Ltd, New York, NY, USA |
| PCV14 |
| COST-OF-ILLNESS STUDY OF UNSTABLE ANGINA PECTORIS IN GERMANY
Smala A1, Schramm B1, Karmann B2, Wendel-Busch J2, Berger K1, 1MERG - Medical Economics Research Group, Munich, Germany; 2Essex Pharma GmbH, Munich, Germany |
| PCV15 |
| CHRONIC VENOUS INSUFFICENCY (CVI) IN POLAND - A COST OF ILLNESS STUDY
Czech M, Faluta T, Pachocki R, Servier Polska, Warsaw, Poland |
| PCV16 |
| COST-EFFECTIVENESS OF AMLODIPINE TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE IN THE U.K
Doyle J1, Arocho R2, Arikian S1, Casciano J1, Kugel H1, Marchant N3, Casciano R1, 1The Analytica Group, New York, NY, USA; 2Pfizer Ltd, New York, NY, USA; 3Pfizer Ltd, Sandwich, Kent, UK |
| PCV17 |
| ECONOMIC EVALUATION OF ENOXAPARIN IN PATIENTS WITH ACUTE MEDICAL ILLNESS: AN ITALIAN ECONOMIC STUDY FROM THE MEDENOX TRIAL
Nuijten M1, Berto P2, Kosa J1, Nadipelli V3, 1Medtap International, Jisp, Netherlands; 2PBE Consulting, Verona, Italy; 3Aventis Pharmaceuticals, Inc, Bridgewater, NJ, USA |
| PCV18 |
| COST EFFECTIVENESS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR THE PROPHYLAXIS OF DVT AND SUBSEQUENT LONG-TERM COMPLICATIONS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED KINGDOM
Botteman M1, Cohen AT2, Nadipelli V3, Stephens J1, Pashos CL4, Caprini J5, 1Abt Associates Clinical Trials, Bethesda, MD; 2Guy's, King's & St. Thomas' School of Medicine, London, UK; 3Aventis Pharmaceuticals, Inc, Bridgewater, NJ; 4Abt Associates Clinical Trials, Cambridge, MA; 5Evanston Hospital, Evanston, IL |
| PCV19 |
| A COST-EFFECTIVENESS ANALYSIS OF THE USE OF CARVEDILOL COMPARED TO BISOPROLOL IN CHRONIC HEART FAILURE
Squire I1, Hebborn A2, Ratcliffe A3, McGuire A4, 1University of Leicester, Leicester, UK; 2F. Hoffman-La Roche, Basel, Switzerland; 3Roche Products Ltd, Welwyn Garden City, UK; 4City University London, London, UK |
| PCV20 |
| COST-EFFECTIVENESS STUDY TO DETERMINE THE IMPACT OF A TOBACCO OUTREACH PROGRAM FOR ADOLESCENTS
Lal L, Philip O, Mehta C, Texas Southern University, Houston, TX, USA |
| PCV21 |
| A HEALTH ECONOMIC ANALYSIS OF THE USE OF AMLODIPINE IN PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN THE U.K
Casciano R1, Doyle J1, Thaulow E2, Casciano J1, Kopp Z3, Marchant N4, 1The Analytica Group, New York, NY, USA; 2University Hospital Oslo, Baerum Postterminal, Sandvika, Norway; 3Pfizer, New York, NY, USA; 4Pfizer Ltd, Sandwich, Kent, UK |
| PCV22 |
| COST-EFFECTIVENESS OF ENOXAPARIN AS VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
de Lissovoy G1, Subedi P1, Nadipelli V2, 1MEDTAP International, Bethesda, MD; 2Aventis Pharmaceuticals, Inc, Bridgewater, NJ |
| PCV23 |
| MODELLING THE COSTS OF ILLNESS IN THE MANAGEMENT OF CEREBROVASCULAR ACCIDENT IN FRANCE
Mègnigbêto A1, Launois R1, Giroud M2, Bail JN3, 1REES France, PARIS, France; 2Centre Hospitalier Universitaire Dijon, Dijon, France; 3Glaxo Smith Kline, Marly Le Roi, France |
| PCV24 |
| COSTS OF HYPERTENSION IN POLAND
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2, 1Drugs Institute in Warsaw, Warsaw, Poland; 2Servier Polska, Warsaw, Poland |
| PCV25 |
| A COST STUDY OF COMMON PRACTICE TREATMENT FOR CRITICAL LIMB ISCHEMIA IN MOSCOW, RUSSIA
Vorobjov P1, Avxentieva M1, Gerasimov V2, Derkach E3, 1Moscow Medical Academy, Moscow, Russia; 2Scientific Center for State Control and Expertise of Drugs, Moscow, Russia; 3Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia |
| PCV26 |
| HOW MUCH DOES ONE GRAM OF HUMAN HEART MUSCLE COST?
Czech M1, Pachocki R1, Kuzniar J2, Splawinski J3, 1Servier Polska, Warsaw, Poland; 2Szpital Wojewodzki nr 2, Rzeszow, Poland; 3Drug Institute, Warsaw, Poland |
| PCV27 |
| COST-EFFECTIVENESS ANALYSIS OF A CHEST PAIN UNIT - A RE-STRUCTURED APPROACH IN RISK STRATIFICATION OF CHEST PAIN
You JH, Lee MW, Poon TL, Lee KK, Ho SS, Sanderson JE, Rainer TH, Sung JJ, The Chinese University of Hong Kong, Hong Kong, China |
| PCV28 |
| COST-CONSEQUENCES OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) COMPARED WITH HEPARIN IN UNSTABLE CORONARY ARTERY DISEASE IN JAPAN
Kamae I1, Nishimura K2, Yanagisawa S1, Hiraga S1, Aino H1, Hata K3, Akita H3, Doherty J4, 1Kobe University, Kobe, Japan; 2Harvard University, Boston, MA, USA; 3Kobe University Hospital, Kobe, Japan, 4Pharmacia Inc, Tokyo, Japan |
| PCV29 |
| PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY: A PHARMACO-UTILIZATION AND PHARMACO-ECONOMIC ANALYSIS
Valpiani G1, Degli Esposti L1, Saragoni S1, Degli Esposti E2, 1CliCon Srl - Health, Economics and Outcomes Research, Ravenna, Italy; 2Health Directorate, Ravenna Local Health Unit, Ravenna, Italy |
| PCV30 |
| A POPULATION-BASED EUROPEAN STUDY OF PERSISTENCE IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
Gabriel S, Dinet J, Guilhaume C, Carita P, Sanofi-Synthelabo, Bagneux, France |
| PCV31 |
| A DECISION-ANALYSIS MODEL FOR ENHANCING MEDICATION ADHERENCE IN PATIENTS TAKING STATINS
Peterson AM1, McGhan WF2, 1Philadelphia College of Pharmacy, Philadelphia, PA, USA; 2University of the Sciences, Philadelphia, PA, USA |
| PCV32 |
| DEVELOPMENT OF TWO INSTRUMENTS: ONE TO MEASURE EDUCATIONAL MATERIAL ACCEPTABILITY AND ONE TO MEASURE KNOWLEDGE GAINED IN PATIENTS WITH HEART FAILURE
Gwadry-Sridhar FH1, Guyatt GH2, Nadeau L3, Calhoun M3, Arnold JMO3, 1McMaster University and University of Western Ontario, London, ON, Canada; 2McMaster University, Hamilton, ON, Canada; 3London Health Sciences Centre, UWO, London, ON, Canada |
| PCV33 |
| IMPACT OF INSURANCE TYPES ON PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION: DIURETICS OR BETA-BLOCKERS VS. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR CALCIUM CHANNEL BLOCKERS
Guo D, Fu Z, Liu G, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| PCV34 |
| STOP SMOKING CESSATION TARGET: OBSERVATION PROGRAM, THE FRENCH PHARMACIST'S PROGRESS
Rouzeau P1, Zabotto E2, Myon E3, Taïeb C3, 1Hopital Purpan, Toulouse, France; 2Pierre Fabre Santé, Castres, France; 3bioMérieux-Pierre Fabre, Boulogne Billancourt, France |
| PCV35 |
| STOP SMOKING CESSATION TARGET: OBSERVATION PROGRAM AN EX-SMOKER IS A SMOKER IN PROGRESSION
Lagrue G1, Myon E2, Taïeb C2, 1Hopital Albert Chenevier, Creteil, France; 2bioMérieux-Pierre Fabre, Boulogne Billancourt, France |
|
|
| DIABETES & GASTROINTESTINAL DISORDERS |
| PDG1 |
| THE OUTCOMES OF LONG-TERM TREATMENT OF A NEW ORAL DIABETES DRUG PIOGLITAZONE (ACTOS ”) IN THE MANAGEMENT OF TYPE 2 DIABETES IN FINLAND
Maniadakis N1, Kielhorn A2, Heikkinen K3, Brandt A4, Jansen R2, 1Eli Lilly, Windlesham Surrey, United Kingdom; 2Eli Lilly, Windlesham, Surrey, United Kingdom; 3Eli Lilly, Vantaa, Finland; 4Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland |
| PDG2 |
| RISK OF DIABETES AMONG RISPERIDONE AND OLANZAPINE USERS
Moisan J1, Grégoire JP1, Gaudet M2, 1Université Laval, Québec, QC, Canada; 2Hôpital du Saint-Sacrement du CHA, Québec, QC, Canada |
| PDG3 |
| AN ECONOMIC EVALUATION OF COMBINATION THERAPY WITH PIOGLITAZONE (ACTOS”, TAKEDA) IN TYPE 2 DIABETES MELLITUS FROM A SPANISH HEALTH-CARE PERSPECTIVE
Maniadakis N1, Sacristan J2, Reviriego J2, Hart W3, Jansen R4, Kielhorn A4, Brandt A5, 1Eli Lilly, Windlesham Surrey, United Kingdom; 2Eli Lilly, Madrid, Spain; 3Health Outcomes, Madrid, Spain; 4Eli Lilly, Windlesham, Surrey, United Kingdom; 5Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland |
| PDG4 |
| THE DIFFERENTIAL EFFECT OF SULPHONYLUREA OR BIGUANIDE DRUGS ON CARDIAC REVASCULARIZATION PROCEDURES IN DIABETICS
Shilo L, Klang S, Bar-Joseph N, Hamerman A, Lieberman N, Porat A, Peterburg Y, Clalit Health Services, Tel Aviv, Israel |
| PDG5 |
| MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE
Brun-Strang C1, Caro J2, Annemans L3, O'Brien J2, Everhard F4, Grueger J4, 1Novartis Pharma S.A, Rueil-Malmaison, France; 2Caro Research Institute, Concord, MA, USA; 3HEDM, Meise, Belgium; 4Novartis Pharmaceuticals AG, Basel, Switzerland |
| PDG6 |
| COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS”, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN
Henriksson F1, Brandt A2, Thomander L3, Kielhorn A4, Jansen R4, Maniadakis N5, 1Stockholm School of Economics, Stockholm, Sweden; 2Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland; 3Eli Lilly, Stockholm, Sweden; 4Eli Lilly, Windlesham, Surrey, UK; 5Eli Lilly, Windlesham Surrey, UK |
| PDG7 |
| THE LIFETIME DIRECT MEDICAL COSTS OF MANAGING DIABETES AND ITS COMPLICATIONS IN FRANCE
Grueger J1, O'Brien JA2, Caro JJ2, Brun C3, Everhard F1, 1Novartis Pharmaceuticals AG, Basel, Switzerland; 2Caro Research Institute, Concord, MA, USA; 3Novartis Pharma, RUEIL MALMAISON, France |
| PDG8 |
| A POPULATION STUDY OF HEALTH-CARE COSTS ASSOCIATED WITH HYPOGLYCAEMIA
Wang J1, Broomhall J1, Leese G2, Morrison B2, Morris A1, Davey P3, 1MEMO, University of Dundee, Dundee, UK; 2Tayside University Hospitals Trust, Dundee, UK; 3MEMO, University of Dundee, Dundee, Scotland, UK |
| PDG9 |
| THE EVENT AND STATE COST OF COMPLICATIONS OF DIABETES IN THE NETHERLANDS
Koopmanschap MA1, van den Boom G2, O'Brien J3, Grueger J4, 1Erasmus University, Rotterdam, Netherlands; 2Novartis Pharma, Arnhem, Netherlands; 3Caro Research, Concord, MA, USA; 4Novartis Pharmaceuticals AG, Basel, Switzerland |
PDG10 |
|
A PHARMACOECONOMIC MODEL OF HbA1C CONTROL IN THE TREATMENT OF TYPE 2 DIABETES
Lilliu H1, Bonastre J1, Cabrieres L2, 1Clp-santé, Paris, France; 2Merck Lipha SA, Lyon Cedex 08, France |
| PDG11 |
| HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOS”, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY
Brandt A1, Frislid K2, Jansen R3, Maniadakis N4, Kielhorn A3, 1Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland; 2Eli Lilly, Oslo, Norway; 3Eli Lilly, Windlesham, Surrey, UK; 4Eli Lilly, Windlesham Surrey, UK |
| PDG12 |
| CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS
van den Boom G1, Koopmanschap MA2, Caro J3, Grueger J4, 1Novartis Pharma, Arnhem, Netherlands; 2Erasmus University, Rotterdam, Netherlands; 3Caro Research Institute, Concord, MA, USA; 4Novartis Pharmaceuticals AG, Basel, Switzerland |
| PDG13 |
| ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY- AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES
Goertz A1, Spannheimer A2, Reitberger U2, Liebl A3, Wagenpfeil S4, 1GlaxoSmithKline, Munich, Germany; 2Kendle International Inc, Munich, Germany; 3Diabetes Stoffwechselzentrum Tegernsee, Rottach-Egern, Germany; 4Institute for Medical Statistics and Epidemiology at Technical University Munich, Munich, Germany |
| PDG14 |
| AN ASSESSMENT OF THE COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS”, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK
Jansen R1, Clausen JO2, Maniadakis N3, Kielhorn A1, Brandt A4, 1Eli Lilly, Windlesham, Surrey, UK; 2Eli Lilly, Copenhagen, Denmark; 3Eli Lilly, Windlesham Surrey, UK; 4Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland |
| PDG15 |
| THE COST OF TREATING DIABETIC FOOT ULCERS (DFU) WITH APLIGRAF IN THE NETHERLANDS
McDonnell J1, Redekop K1, Verboom P1, Lovas K2, Kalo Z3, 1Erasmus University, Rotterdam, Netherlands; 2Semmelweis University, Budapest, Hungary; 3Novartis Pharma AG, Basel, Switzerland |
| PDG16 |
| BUDGETARY IMPACT OF TREATMENT GUIDELINES - THE EXAMPLE OF TYPE 2 DIABETES
Pirk O1, Goertz A2, Spannheimer A3, Reitberger U3, Liebl A4, 1Fricke & Pirk, Nuremberg, Germany; 2GlaxoSmithKline, Munich, Germany; 3Kendle International Inc, Munich, Germany; 4Diabetes Stoffwechselzentrum Tegernsee, Rottach-Egern, Germany |
| PDG17 |
| AN ECONOMIC ANALYSIS OF IRBESARTAN IN TYPE II DIABETIC NEPHROPATHY
Rodby R1, Simon TA2, Chen R2, L'Italien G3, Waldeck R3, Yuan Y2, Lewis E1, 1Rush Presbyterian/St. Luke's Medical Center, Chicago, IL, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA |
| PDG18 |
| TREATMENT CHANGE FOLLOWING HEMOGLOBIN A1C TEST RESULTS AMONG DIABETIC PATIENTS
Schabert V1, Zhang M2, Esposito D1, Neslusan C2, Conklin J1, Cohen F3, 1The MEDSTAT Group, Santa Barbara, CA, USA; 2Pharmaceutical Group Strategic Marketing, Raritan, NJ, USA; 3R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA |
| PDG19 |
| TRENDS IN USE OF ANTIDIABETICS IN THE CZECH REPUBLIC
Sechser T, Pelikanova T, Institute for Clinical and Experimental Medicine, Prague, Czech Republic |
| PDG20 |
| A SIMULATION MODEL TO CALCULATE LONG-TERM COSTS AND LIFE EXPECTANCY DEPENDENT ON POST PRANDIAL BLOOD GLUCOSE LEVELS IN DIABETES PATIENTS
Palmer AJ1, Roze S1, Nicklasson L2, Foos V1, 1CORE Center for Outcomes Research, BASEL, Switzerland; 2Novo Nordisk A/S, Bagsvaerd, Denmark |
| PDG21 |
| HUMANISTIC IMPACT OF HYPERGLYCEMIA IN TYPE 1 DIABETES MELLITUS
Summers KH1, Cox D2, Kotvatchev B2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2University of Virginia Health System, Charlottesville, VA, USA |
| PDG22 |
|
EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES: A PILOT STUDY
Wee HL1, Lee WWR2, Li SC1, Wee HL1, 1National University of Singapore, Singapore, Singapore; 2KK Women and Children's Hospital, Singapore, Singapore |
| PDG23 |
| PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT: THE EFFECTS OF THE INTRODUCTION OF A DISEASE MANAGEMENT GUIDELINE
Degli Esposti L1, Valpiani G1, Saragoni S1, Triossi O2, Degli Esposti E3, 1CliCon Srl - Health, Economics and Outcomes Research, Ravenna, Italy, Ravenna, Italy; 2Gastroenterology Department of S. Maria delle Croci Hospital, Ravenna, Italy; 3Health Directorate, Ravenna Local Health Unit, Ravenna, Italy |
| PDG24 |
| PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA
Snegova E1, Churilin Y2, Moisseyev S3, Mokhov O3, Adamyan N3, 1Center for Pharmacoeconomic Research, Moscow, Russia; 2Center for Pharmacoeconomic Research, Russia; 3Moscow Medical Academy, Moscow, Russia |
| PDG25 |
| ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD
Beard S, Gaffney L, RTI Health Solutions, Manchester, UK |
| PDG26 |
| THE IMPACT OF THE USE OF NEXIUM ON THE OVERALL PPI BUDGET IN GREECE
Christodoulopoulou A, Karokis A, AstraZeneca SA, Athens, Greece |
| PDG27 |
| HEALTH STATE UTILITIES IN GERD PATIENTS WITH HEARTBURN; A STUDY IN GERMANY AND SWEDEN
Kartman B1, Gatz G2, Johannesson M3, 1AstraZeneca R&D, Mölndal, Sweden; 2Byk Gulden, Konstanz, Germany; 3Stockholm School of Economics, Stockholm, Sweden |
|
|
| ALLERGY, EYE, EAR & SKIN DISORDERS |
| PEE1 |
| LONG TERM CLINICAL CONSEQUENCES OF ND:YAG LASER CAPSULOTOMY FOLLOWING POSTERIOR CAPSULAR OPACIFICATION AFTER CATARACT SURGERY - A MARKOV MODEL APPROACH
Billotte C1, Berdeaux G2, 1Chu de Caen, Caen, France; 2Alcon, Rueil-Malmaison, France |
| PEE2 |
| COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS LEVOCABASTINE 0.05% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS
Lafuma A1, Fagnani F1, Nuijten M2, Berdeaux G3, 1Cemka, Bourg-La-Reine, France; 2Medtap International, Jisp, Netherlands; 3Alcon, Rueil-Malmaison, France |
| PEE3 |
| COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS CROMOLYN SODIUM 2% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS
Lafuma A1, Fagnani F1, Nuijten M2, Berdeaux G3, 1Cemka, Bourg-La-Reine, France; 2Medtap International, Jisp, Netherlands; 3Alcon, Rueil-Malmaison, France |
| PEE4 |
| WELFARE COSTS OF VISUAL IMPAIRMENT
Remak E1, Chambers M1, Kennedy-Martin T2, 1Medtap International, London, UK; 2Lilly, Surrey, UK |
| PEE5 |
| COSTS AND CONSEQUENCES OF LASIK, GLASSES AND CONTACT LENSES IN MILD TO MODERATE MYOPIA - A SPANISH SOCIETAL APPROACH
Alio y Sanz J1, Martinez J2, Magaz S3, Badia X3, Berdeaux G4, 1Insituto Oftalmologico de Alicante, Alicante, Spain; 2Instituto Oftalmologico de Alicante, Alicante, Spain; 3Health Outcomes Research Europe, Barcelona, Spain; 4Alcon, Rueil-Malmaison, France |
| PEE6 |
| PROSTAMIDES VS. COMBINATION PRODUCTS FOR GLAUCOMA TREATMENT: EFFECTIVENESS AND COST CONSIDERATIONS
Evans S1, Doyle J1, Casciano J1, Steeds C2, Walt J3, 1The Analytica Group, New York, NY, USA; 2Allergan Ltd, Buckinghamshire, UK; 3Allergan Inc, Irvine, CA, USA |
| PEE7 |
|
THE BURDEN OF AGE-RELATED MACULAR DEGENERATION - RESULTS OF A COHORT STUDY IN TWO FRENCH REFERRAL CARE CENTERS
Bonastre J1, Le Pen C2, Soubrane G3, Quentel G4, 1Clp-santé, Paris, France; 2Université Paris Dauphine, Paris, France; 3Centre Hospitalier Intercommunal de Créteil, Créteil, France; 4Centre ophtalmologique d'Imagerie et de Laser, Paris, France |
| PEE8 |
| QUALITY OF LIFE OF FRENCH PATIENTS TREATED FOR PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Auzanneau N1, Touboul C1, Berdeaux G2, 1Taylor Nelson Sofres, Montrouge, France; 2Alcon, Rueil-Malmaison, France |
| PEE9 |
| THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY
Banz K1, Klein W2, Brunella A1, 1Outcomes International, Basel, Switzerland; 2Fujisawa GmbH, Munich, Germany |
| PEE10 |
|
IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS?
Macario A1, Dexter F2, 1Stanford University, Stanford, CA, USA; 2Univeristy of Iowa, Iowa City, IA, USA |
| PEE11 |
| PSORIASIS AND EVERYDAY LIFE: FIRST RESULTS
Corvest M1, Lefrançois P2, Myon E3, Taïeb C3, 1Association Pour La Lutte Contre Le Psoriasis, Eragny, France; 2Pierre Fabre Dermatologie, Lavaur, France; 3bioMérieux-Pierre Fabre, Boulogne Billancourt, France |
| PEE12 |
| THE WILLINGNESS TO PAY FOR PHARMACOTHERAPY OF ATOPIC DERMATITIS
Ikeda S1, Tamura M2, Yamaki S3, Nakagawa H4, 1Keio University, Tokyo, Japan; 2International University of Health and Welfare, Otawara, Japan; 3University of Tokyo, Tokyo, Japan; 4Jichi Medical School, Tochigi, Japan |
|
|
| NEUROLOGICAL DISORDERS |
| PND1 |
| ASSOCIATION OF FAMILY HARDINESS WITH WORK PRODUCTIVITY AND ACTIVITY IN FAMILIES OF PEDIATRIC PATIENTS WITH EPILEPSY
Meek PD, Gidal BE, Sheth R, Hermann BP, University of Wisconsin at Madison, Madison, WI, USA |
| PND2 |
| COMPARISON OF ADVERSE REACTION REPORTS FOR RIVASTIGMINE AND DONEPEZIL USING THE FDA'S ADVERSE EVENT REPORTING SYSTEM
Rizzo J1, Chang S2, Cohen A2, 1The Ohio State University, Columbus, OH, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA |
| PND3 |
| COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE
Dodel RC1, Volkmann J2, Spottke AE1, Smala A3, Berger K3, Krack P2, Oertel WH1, 1Philipps-University Marburg, Marburg, Germany; 2Albrechts-University, Kiel, Germany; 3MERG - Medical Economics Research Group, Munich, Germany |
| PND4 |
| THE IMPACT OF DRUG INTERACTIONS ON HOSPITALIZATION RATES FOR ALZHEIMER'S PATIENTS TREATED WITH DONEPEZIL
Rizzo J1, Chang S2, Cohen A2, 1The Ohio State University, Columbus, OH, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA |
| PND5 |
| THE COST OF SECONDARY STROKE IN POLAND
Niewada MP1, Kamiñski B2, Kobayashi A1, Cz_onkowska A3, Cz_onkowski A1, Czech M4, 1Medical University of Warsaw, Warsaw, Poland; 2Warsaw School of Economics, Warsaw, Poland; 3Institute of Psychiatry and Neurology, Warsaw, Poland; 4Servier Polska, Warsaw, Poland |
| PND6 |
| ASSESSING THE COSTS OF PARKINSON'S DISEASE IN GERMANY
Spottke AE1, Reuter M1, Smala A2, Berger K2, Athen O3, Köhne-Volland R3, Meyer D3, Oertel WH1, Dodel RC1, 1Philipps-University Marburg, Marburg, Germany, 2MERG - Medical Economics Research Group, Munich, Germany, 3Metronomia, Munich, Germany |
| PND7 |
| ESTIMATION OF THE COSTS OF MULTIPLE SCLEROSIS BASED ON 157 FRENCH PATIENTS
Marissal JP1, Hautecoeur P2, 1CRESGE-LABORES, Lille, France; 2Saint-Philibert Hospital, Lomme, France |
| PND8 |
| IMPLICATIONS OF PRESCRIBING FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): INTRODUCING A TREATMENT ALGORITHM FOR GLATIRAMER ACETATE (COPAXONE)
Brambleby P1, Bose UK2, Stanley S3, 1Norfolk Health Authority, Norwich, UK; 2Aventis Pharma UK, West Malling, Kent, UK; 3Competitive Partnerships, Herts, UK |
| PND9 |
| IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMER'S DISEASE
Jackson A1, Chang S2, Cohen A3, 1Prescription Solutions, Costa Mesa, CA, USA; 2Novartis Pharmaceuticals, East Hanover, NJ, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA |
| PND10 |
| CONCOMITANT DRUG USE IMPLICATIONS IN ALZEIMER'S DISEASE PATIENTS USING DONEPEZIL
Jackson A1, Opler M2, 1Prescription Solutions, Costa Mesa, CA, USA; 2Columbia University, New York, NY, USA |
| PND11 |
| DISEASE MANAGEMENT IN MIGRAINE AND TENSION-TYPE HEADACHE - RESULTS OF A SOCIO-ECONOMIC PILOT STUDY
Schipp B1, Hanisch M2, Hegewald S1, Behrens M3, 1Dresden University of Technology, Dresden, Germany; 2University Hospital, Dresden, Germany; 3GlaxoSmithKline, Muenchen, Germany |
| PND12 |
| TREATMENT AND HEALTH-CARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES
Mackell JA1, McDonnell DD2, 1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
| PND13 |
| TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES
Mackell JA1, McDonnell DD2, 1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
| PND14 |
| QUALITY OF LIFE OF WOMEN SUFFERING FROM MENSTRUAL MIGRAINE AND RELATIONSHIP WITH MOOD
Arpinelli F, Visona G, Roncolato M, Medical Dept. GlaxoSmithKline S.p.A, Verona, Italy |
| PND15 |
| COST-EFFECTIVENESS OF THERAPY FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): INTRODUCING AN ECONOMIC MODEL FOR COPAXONE (GLATIRAMER ACETATE)
Bose UK, Aventis Pharma UK, West Malling, Kent, UK |
|
